[1]
Stoffel, S.T., von Moos, R., Thürlimann, B., Cathomas, R., Gillessen, S., Zürrer-Härdi, U., von Briel, T., Anchisi, S., Feller, A., Schär, C., Dietrich, D., Schwenkglenks, M., Lupatsch, J.E. and Mark, M. 2021. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. Swiss Medical Weekly. 151, 0910 (Mar. 2021), w20464. DOI:https://doi.org/10.4414/smw.2021.20464.